Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- LDP’s Takemi Says NHI Prices Will Probably Be Cut for 3 Years in a Row
January 16, 2015
- MHLW Approves Plan to Include Hepatitis B Vaccines in Public Vaccination Programs
January 16, 2015
- 1.9 Billion Yen Allocated to Speed Up Regulatory Reviews
January 15, 2015
- 124.8 Billion Yen Earmarked in FY2015 Budget for AMED
January 15, 2015
- AJMC to Announce Guidelines for Investigator-Led Clinical Trials Next Month
January 15, 2015
- Japan Govt OKs FY2015 Tax Reform Plan
January 15, 2015
- Editor’s Pick: Five Healthcare News Headlines for Dec. 29 - Jan. 11
January 14, 2015
- Cabinet OKs Extra Budget, 3.5 Billion Yen Allocated for IFN-Free Treatment
January 13, 2015
- Panel Agrees to Add Hepatitis B Vaccines to Public Immunization Program
January 13, 2015
- MHLW Calls for Revision of Package Inserts for SGLT-2 Inhibitors
January 13, 2015
- FY2015 Budget to Earmark 47 Billion Yen to Promote Healthcare R&D
January 9, 2015
- PAFSC 2nd Committee to Discuss Eisai’s Anticancer Agent on Jan. 21
January 9, 2015
- 30% R&D Tax Deduction Cap Could Be Secured with Open Innovation Tax Break: Economic Affairs Division
January 8, 2015
- 2015 to Be “Starting Year for Major Reform” of Healthcare and Nursing Insurance Systems: Health Minister
January 8, 2015
- Public Trust Indispensable for Industry Development: Mr Futagawa of Health Policy Bureau
January 7, 2015
- Pharmaceutical and Food Safety Bureau to Promote Prescription-to-OTC Switches Based on Industry Opinions
January 6, 2015
- MHLW OKs 31 Products Including Takeda’s Vonoprazan
January 5, 2015
- Ruling Parties Settle on 25%-Plus-5% Cap for R&D Tax Credit
January 5, 2015
- Health Minister Shiozaki Reappointed
December 25, 2014
- LDP Study Group Shows Sense of Crisis over Reduction of R&D Tax Deduction Cap
December 25, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…